

Paramala J Santosh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9493941/publications.pdf>

Version: 2024-02-01

108
papers

5,321
citations

117625

34
h-index

91884

69
g-index

117
all docs

117
docs citations

117
times ranked

5451
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of managed transition on mental health outcomes for young people at the childâ€‘adult mental health service boundary: a randomised clinical trial. <i>Psychological Medicine</i> , 2023, 53, 2193-2204.	4.5	18
2	Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2023, 62, 151-168.	0.5	22
3	Age-related brain deviations and aggression. <i>Psychological Medicine</i> , 2023, 53, 4012-4021.	4.5	10
4	Subgrouping children and adolescents with disruptive behaviors: symptom profiles and the role of callousâ€‘unemotional traits. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 51-66.	4.7	9
5	The effects of callous-unemotional traits and aggression subtypes on amygdala activity in response to negative faces. <i>Psychological Medicine</i> , 2022, 52, 476-484.	4.5	18
6	Autism Spectrum Disorder and Clinical High Risk for Psychosis: A Systematic Review and Meta-analysis. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 1568-1586.	2.7	18
7	Improving the experience of obtaining repeat complex paediatric prescriptions in the UK. <i>Archives of Disease in Childhood</i> , 2022, , archdischild-2020-320912.	1.9	1
8	Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	26
9	Catatonia in autism spectrum disorders: A systematic review and meta-analysis. <i>European Psychiatry</i> , 2022, 65, 1-22.	0.2	37
10	Repurposing fluvoxamine, and other psychiatric medications, for <scp>COVID</scp>â€‘19 and other conditions. <i>World Psychiatry</i> , 2022, 21, 314-315.	10.4	4
11	Transition from child and adolescent mental health care to adult services for young people with Attention-Deficit/Hyperactivity Disorder (ADHD) or Autism Spectrum Disorder (ASD) in Europe: Barriers and recommendations. <i>L'Encephale</i> , 2022, 48, 555-559.	0.9	4
12	An Observational Study of Heart Rate Variability Using Wearable Sensors Provides a Target for Therapeutic Monitoring of Autonomic Dysregulation in Patients with Rett Syndrome. <i>Biomedicines</i> , 2022, 10, 1684.	3.2	6
13	Development and Psychometric Properties of a New Questionnaire to Assess Mental Health and Concerning Behaviors in Children and Young People with Autism Spectrum Disorder (ASD): The Assessment of Concerning Behavior (ACB) Scale. <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 2812-2828.	2.7	9
14	Aggression subtypes relate to distinct resting state functional connectivity in children and adolescents with disruptive behavior. <i>European Child and Adolescent Psychiatry</i> , 2021, 30, 1237-1249.	4.7	18
15	Adiposity and cardiovascular outcomes in threeâ€‘yearâ€‘old children of participants in <scp>UPBEAT</scp>, an <scp>RCT</scp> of a complex intervention in pregnant women with obesity. <i>Pediatric Obesity</i> , 2021, 16, e12725.	2.8	25
16	Reward and Punishment Sensitivity are Associated with Cross-disorder Traits. <i>Psychiatry Research</i> , 2021, 298, 113795.	3.3	4
17	Emotional Behavioural and Autonomic Dysregulation (EBAD) in Rett Syndrome â€‘ EDA and HRV monitoring using wearable sensor technology. <i>Journal of Psychiatric Research</i> , 2021, 138, 186-193.	3.1	14
18	Parent-Mediated Interventions for Infants under 24 Months at Risk for Autism Spectrum Disorder: A Systematic Review of Randomized Controlled Trials. <i>Journal of Autism and Developmental Disorders</i> , 2021, , 1.	2.7	2

#	ARTICLE	IF	CITATIONS
19	Movement disorders in patients with Rett syndrome: A systematic review of evidence and associated clinical considerations. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 369-393.	1.8	11
20	Cohort profile: demographic and clinical characteristics of the MILESTONE longitudinal cohort of young people approaching the upper age limit of their child mental health care service in Europe. <i>BMJ Open</i> , 2021, 11, e053373.	1.9	8
21	Development and psychometric properties of the "Suicidality: Treatment Occurring in Paediatrics (STOP) Risk and Resilience Factors Scales" in adolescents. <i>European Child and Adolescent Psychiatry</i> , 2020, 29, 153-165.	4.7	5
22	Psychosocial risk factors for suicidality in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2020, 29, 759-776.	4.7	187
23	Transition as a topic in psychiatry training throughout Europe: trainees' perspectives. <i>European Child and Adolescent Psychiatry</i> , 2020, 29, 41-49.	4.7	12
24	Organic features of autonomic dysregulation in paediatric brain injury " Clinical and research implications for the management of patients with Rett syndrome. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 118, 809-827.	6.1	5
25	Specific cortical and subcortical alterations for reactive and proactive aggression in children and adolescents with disruptive behavior. <i>NeuroImage: Clinical</i> , 2020, 27, 102344.	2.7	13
26	Transitioning from child to adult mental health services: what role for social services? Insights from a European survey. <i>Journal of Children's Services</i> , 2020, 15, 89-108.	0.7	0
27	Differentiating Females with Rett Syndrome and Those with Multi-Comorbid Autism Spectrum Disorder Using Physiological Biomarkers: A Novel Approach. <i>Journal of Clinical Medicine</i> , 2020, 9, 2842.	2.4	6
28	The effects of callous-unemotional traits and aggression subtypes on amygdala activity in response to negative faces " ERRATUM. <i>Psychological Medicine</i> , 2020, , 1-1.	4.5	9
29	Autonomic dysfunction and sudden death in patients with Rett syndrome: a systematic review. <i>Journal of Psychiatry and Neuroscience</i> , 2020, 45, 150-181.	2.4	21
30	Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, e15.	5.6	27
31	A cross-cultural qualitative study of the ethical aspects in the transition from child mental health services to adult mental health services. <i>Child and Adolescent Mental Health</i> , 2020, 25, 143-149.	3.5	5
32	Executive functioning and emotion recognition in youth with oppositional defiant disorder and/or conduct disorder. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 539-551.	2.6	14
33	Validation of the Transition Readiness and Appropriateness Measure (TRAM) for the Managing the Link and Strengthening Transition from Child to Adult Mental Healthcare in Europe (MILESTONE) study. <i>BMJ Open</i> , 2020, 10, e033324.	1.9	21
34	Continuity of Care and Mental Health Service Use Among Medicaid-enrolled Youths. <i>Medical Care</i> , 2020, 58, 199-207.	2.4	8
35	ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 412-414.	5.6	163
36	Protocol for the development and validation procedure of the managing the link and strengthening transition from child to adult mental health care (MILESTONE) suite of measures. <i>BMC Pediatrics</i> , 2020, 20, 167.	1.7	10

#	ARTICLE	IF	CITATIONS
37	Autonomic Characteristics of Sudden Unexpected Death in Epilepsy in Children—A Systematic Review of Studies and Their Relevance to the Management of Epilepsy in Rett Syndrome. <i>Frontiers in Neurology</i> , 2020, 11, 632510.	2.4	4
38	Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1561.	7.4	60
39	Distinct associations between fronto-striatal glutamate concentrations and callous-unemotional traits and proactive aggression in disruptive behavior. <i>Cortex</i> , 2019, 121, 135-146.	2.4	10
40	A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study. <i>BMJ Open</i> , 2019, 9, e033827.	1.9	3
41	Putative Mechanisms of Action and Clinical Use of Lithium in Children and Adolescents: A Critical Review. <i>Current Neuropharmacology</i> , 2019, 17, 318-341.	2.9	23
42	Propranolol for treating emotional, behavioural, autonomic dysregulation in children and adolescents with autism spectrum disorders. <i>Journal of Psychopharmacology</i> , 2018, 32, 641-653.	4.0	34
43	The interface between child/adolescent and adult mental health services: results from a European 28-country survey. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 501-511.	4.7	77
44	Patterns of Early Mental Health Diagnosis and Medication Treatment in a Medicaid-Insured Birth Cohort. <i>JAMA Pediatrics</i> , 2018, 172, 576.	6.2	16
45	Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2018, 59, 932-947.	5.2	138
46	Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2018, 32, 3-29.	4.0	196
47	Managing the link and strengthening transition from child to adult mental health Care in Europe (MILESTONE): background, rationale and methodology. <i>BMC Psychiatry</i> , 2018, 18, 167.	2.6	40
48	A systematic review of the literature on ethical aspects of transitional care between child- and adult-orientated health services. <i>BMC Medical Ethics</i> , 2018, 19, 73.	2.4	11
49	Comparing the DSM-5 construct of Disruptive Mood Dysregulation Disorder and ICD-10 Mixed Disorder of Emotion and Conduct in the UK Longitudinal Assessment of Manic Symptoms (UK-LAMS) Study. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 1095-1104.	4.7	7
50	Key issues in Rett syndrome: emotional, behavioural and autonomic dysregulation (EBAD) - a target for clinical trials. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 128.	2.7	24
51	Architecture and functioning of child and adolescent mental health services: a 28-country survey in Europe. <i>Lancet Psychiatry</i> , 2017, 4, 715-724.	7.4	92
52	Stimulant medication to treat attention-deficit/hyperactivity disorder. <i>BMJ: British Medical Journal</i> , 2017, 358, j2945.	2.3	3
53	Development of the Tailored Rett Intervention and Assessment Longitudinal (TRIAL) database and the Rett Evaluation of Symptoms and Treatments (REST) Questionnaire. <i>BMJ Open</i> , 2017, 7, e015342.	1.9	11
54	Pediatric Antipsychotic Use and Outcomes Monitoring. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 546-554.	1.3	14

#	ARTICLE	IF	CITATIONS
55	Protocol for a cohort study of adolescent mental health service users with a nested cluster randomised controlled trial to assess the clinical and cost-effectiveness of managed transition in improving transitions from child to adult mental health services (the MILESTONE study). <i>BMJ Open</i> , 2017, 7, e016055.	1.9	32
56	Paradoxical physiological responses to propranolol in a Rett syndrome patient: a case report. <i>BMC Pediatrics</i> , 2016, 16, 194.	1.7	9
57	Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 444-455.	0.5	223
58	Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents. <i>BJ Psych Advances</i> , 2016, 22, 151-161.	0.7	17
59	Developing and measuring transition-related decision-making in Europe. <i>European Psychiatry</i> , 2016, 33, S58-S58.	0.2	2
60	The European ADHD Guidelines Group replies:. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 1092-1093.	0.5	2
61	Development and psychometric properties of the Suicidality: Treatment Occurring in Paediatrics (STOP) Suicidality Assessment Scale (STOP-SAS) in children and adolescents. <i>BMC Pediatrics</i> , 2016, 16, 213.	1.7	13
62	Protocol for the development and validation of a questionnaire to assess concerning behaviours and mental health in individuals with autism spectrum disorders: the Assessment of Concerning Behaviour (ACB) scale: Table A1. <i>BMJ Open</i> , 2016, 6, e010693.	1.9	8
63	Psychopharmacology of Neurodevelopmental Disorders in Children. , 2016, , 325-362.		3
64	Cognitive Training for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 164-174.	0.5	453
65	Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD. <i>Psychopharmacology</i> , 2015, 232, 2071-2082.	3.1	46
66	Facilitating support groups for siblings of children with neurodevelopmental disorders using audio-conferencing: a longitudinal feasibility study. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2015, 9, 8.	2.5	16
67	Development and psychometric properties of the parent version of the Profile of Neuropsychiatric Symptoms (PONS) in children and adolescents. <i>BMC Pediatrics</i> , 2015, 15, 62.	1.7	10
68	The effect of age on DNA concentration from whole saliva: Implications for the standard isolation method. <i>American Journal of Human Biology</i> , 2014, 26, 859-862.	1.6	3
69	Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. <i>European Child and Adolescent Psychiatry</i> , 2014, 23, 1149-1160.	4.7	23
70	Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2014, 28, 179-203.	4.0	233
71	Treatable metabolic psychoses that go undetected: What Niemann-Pick type C can teach us. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 162-169.	2.4	24
72	A neural systems approach in autism spectrum disorders. <i>Developmental Medicine and Child Neurology</i> , 2012, 54, 206-207.	2.1	0

#	ARTICLE	IF	CITATIONS
73	Efficacy and Tolerability of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder in Adults. <i>CNS Drugs</i> , 2011, 25, 737-763.	5.9	51
74	Dimensions and Latent Classes of Episodic Mania-Like Symptoms in Youth: An Empirical Enquiry. <i>Journal of Abnormal Child Psychology</i> , 2011, 39, 925-937.	3.5	27
75	European guidelines on managing adverse effects of medication for ADHD. <i>European Child and Adolescent Psychiatry</i> , 2011, 20, 17-37.	4.7	302
76	The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. <i>European Child and Adolescent Psychiatry</i> , 2010, 19, 83-105.	4.7	379
77	Eunethydis: a statement of the ethical principles governing the relationship between the European group for ADHD guidelines, and its members, with commercial for-profit organisations. <i>European Child and Adolescent Psychiatry</i> , 2010, 19, 737-739.	4.7	2
78	Youth meeting symptom and impairment criteria for mania-like episodes lasting less than four days: an epidemiological enquiry. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2010, 51, 31-38.	5.2	71
79	Maternal alcohol consumption. <i>London Journal of Primary Care</i> , 2009, 2, 28-35.	0.9	5
80	The construction and validation of a short form of the developmental, diagnostic and dimensional interview. <i>European Child and Adolescent Psychiatry</i> , 2009, 18, 521-524.	4.7	45
81	Treatment of alternating hemiplegia of childhood with aripiprazole. <i>Developmental Medicine and Child Neurology</i> , 2009, 51, 74-77.	2.1	16
82	Psychopharmacological treatment of behavioural problems in Sanfilippo syndrome. <i>BMJ Case Reports</i> , 2009, 2009, bcr0720080480-bcr0720080480.	0.5	1
83	Impact of familiarity upon children's developing facial expression recognition. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2008, 49, 201-210.	5.2	39
84	Paediatric bipolar disorder – an update. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 349-352.	0.2	1
85	Paediatric psychopharmacology – special considerations. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 384-388.	0.2	1
86	Cerebellar growth and behavioural & neuropsychological outcome in preterm adolescents. <i>Brain</i> , 2008, 131, 1344-1351.	7.6	128
87	Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2007, 21, 10-41.	4.0	232
88	Repetitive and stereotyped behaviours in pervasive developmental disorders. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2006, 47, 573-581.	5.2	109
89	Development of an Internet-based real-time system for monitoring pharmacological interventions in children with neurodevelopmental and neuropsychiatric disorders. <i>Child: Care, Health and Development</i> , 2006, 32, 591-600.	1.7	25
90	Does pervasive developmental disorder protect children and adolescents against drug and alcohol use?. <i>European Child and Adolescent Psychiatry</i> , 2006, 15, 183-188.	4.7	60

#	ARTICLE	IF	CITATIONS
91	Long-acting medications for the hyperkinetic disorders. <i>European Child and Adolescent Psychiatry</i> , 2006, 15, 476-495.	4.7	336
92	Refining the diagnoses of inattention and overactivity syndromes: A reanalysis of the Multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. <i>Clinical Neuroscience Research</i> , 2005, 5, 307-314.	0.8	81
93	Paediatric bipolar disorder – an update. <i>Psychiatry (Abingdon, England)</i> , 2005, 4, 101-105.	0.2	4
94	Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH. <i>European Child and Adolescent Psychiatry</i> , 2005, 14, 297-304.	4.7	31
95	12-month efficacy and safety of OROS® MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. <i>European Child and Adolescent Psychiatry</i> , 2005, 14, 305-309.	4.7	37
96	Effects of the Committee on Safety of Medicines Advice on Antidepressant Prescribing to Children and Adolescents in the UK. <i>Drug Safety</i> , 2005, 28, 1151-1157.	3.2	55
97	Social impairment in Hyperkinetic Disorder. <i>European Child and Adolescent Psychiatry</i> , 2004, 13, 141-50.	4.7	67
98	Non-stimulant medications in the treatment of ADHD. <i>European Child and Adolescent Psychiatry</i> , 2004, 13, 1102-16.	4.7	110
99	Use of Selective Serotonin Reuptake Inhibitors in Children and Adolescents. <i>Drug Safety</i> , 2004, 27, 991-1000.	3.2	57
100	Clinical Incidence of Sensory Integration Difficulties in Adults with Learning Disabilities and Illustration of Management. <i>British Journal of Occupational Therapy</i> , 2003, 66, 454-463.	0.9	18
101	Pharmacotherapy of target symptoms in autistic spectrum disorders. <i>Indian Journal of Pediatrics</i> , 2001, 68, 427-431.	0.8	17
102	Clinical considerations in the diagnosis of autism spectrum disorders. <i>Indian Journal of Pediatrics</i> , 2001, 68, 439-449.	0.8	3
103	Stimulant drugs. <i>European Child and Adolescent Psychiatry</i> , 2000, 9, S27-S43.	4.7	70
104	Psychopharmacotherapy in children and adults with intellectual disability. <i>Lancet, The</i> , 1999, 354, 233-242.	13.7	99
105	An Open Clinical Trial of Buspirone in Children With Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1998, 37, 364-371.	0.5	39
106	A study of P300 in melancholic depression – Correlation with psychotic features. <i>Biological Psychiatry</i> , 1994, 35, 474-479.	1.3	51
107	Varied psychiatric manifestations of acute intermittent porphyria. <i>Biological Psychiatry</i> , 1994, 36, 744-747.	1.3	38
108	A Randomised Placebo-Controlled Trial to Determine If Fluoxetine Is Effective for Improving Autistic Behaviours. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0